Oramed Pharmaceuticals Inc. (ORMP) — 8-K Filings

8-K Filings (30)

• Oramed Pharmaceuticals Reports Director/Officer Changes — Dec 31, 2025 Risk: medium
  On December 31, 2025, Oramed Pharmaceuticals Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The f
• Oramed Pharmaceuticals Files 8-K Report — Dec 31, 2025 Risk: low
  On December 30, 2025, Oramed Pharmaceuticals Inc. filed an 8-K report. The filing indicates that the company's fiscal year ends on December 31st. No specific bu
• Oramed Pharmaceuticals Files 8-K on Material Agreement — Nov 17, 2025 Risk: medium
  Oramed Pharmaceuticals Inc. filed an 8-K on November 17, 2025, reporting on a material definitive agreement entered into on November 16, 2025. The filing also c
• Oramed Pharmaceuticals Terminates Material Agreement — Oct 24, 2025 Risk: medium
  On October 20, 2025, Oramed Pharmaceuticals Inc. reported the termination of a material definitive agreement. The company also provided updates on its results o
• Oramed Pharmaceuticals Files 8-K Report — Oct 6, 2025 Risk: low
  On September 30, 2025, Oramed Pharmaceuticals Inc. filed an 8-K report detailing other events. The company, incorporated in Delaware with its principal executiv
• Oramed Pharmaceuticals Reports Director/Officer Changes & Shareholder Votes — Aug 21, 2025 Risk: medium
  Oramed Pharmaceuticals Inc. filed an 8-K on August 21, 2025, reporting on events that occurred on August 19, 2025. The filing indicates changes related to the d
• Oramed Pharmaceuticals Files 8-K: Material Agreement — Jul 23, 2025 Risk: medium
  On July 22, 2025, Oramed Pharmaceuticals Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial
• Oramed Pharmaceuticals Relocates HQ, Updates Contact Info — May 21, 2025 Risk: low
  On May 21, 2025, Oramed Pharmaceuticals Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1185 Avenue of t
• Oramed Pharmaceuticals Enters Material Definitive Agreement — Apr 28, 2025 Risk: medium
  On April 24, 2025, Oramed Pharmaceuticals Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, the
• Oramed Pharmaceuticals Files 8-K with Material Agreement — Mar 3, 2025 Risk: medium
  On February 28, 2025, Oramed Pharmaceuticals Inc. entered into a material definitive agreement. The company also filed financial statements and exhibits as part
• Oramed Pharmaceuticals Enters Material Definitive Agreement — Feb 27, 2025 Risk: medium
  Oramed Pharmaceuticals Inc. announced on February 22, 2025, that it entered into a material definitive agreement. The filing does not disclose specific details
• Oramed Pharmaceuticals Files 8-K with Material Agreement — Feb 11, 2025 Risk: medium
  On February 7, 2025, Oramed Pharmaceuticals Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financ
• Oramed Pharmaceuticals Files 8-K for Material Agreement — Jan 22, 2025 Risk: medium
  Oramed Pharmaceuticals Inc. filed an 8-K on January 22, 2025, reporting a material definitive agreement entered into on January 21, 2025. The filing also includ
• Oramed Pharmaceuticals Files 8-K with Material Agreement — Jan 3, 2025 Risk: medium
  On January 2, 2025, Oramed Pharmaceuticals Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial s
• Oramed Pharmaceuticals Files 8-K Report — Dec 17, 2024 Risk: medium
  On December 13, 2024, Oramed Pharmaceuticals Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific detail
• Oramed Pharmaceuticals Acquires Private Company for $10M — Oct 29, 2024 Risk: medium
  Oramed Pharmaceuticals Inc. announced on October 24, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of
• Oramed Pharmaceuticals Completes Merger with Premal Holdings — Oct 8, 2024 Risk: medium
  Oramed Pharmaceuticals Inc. announced on October 7, 2024, the closing of its previously announced merger with Premal Holdings Corp. The combined company will op
• Oramed Pharmaceuticals Inc. Files 8-K for Material Agreement — Sep 26, 2024 Risk: medium
  On September 23, 2024, Oramed Pharmaceuticals Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal execut
• Oramed Pharmaceuticals Files 8-K — Sep 23, 2024 Risk: low
  Oramed Pharmaceuticals Inc. filed an 8-K on September 23, 2024, reporting other events and financial statements as of September 20, 2024. The filing does not co
• Oramed Pharmaceuticals Holds Shareholder Vote — Aug 2, 2024 Risk: low
  On August 1, 2024, Oramed Pharmaceuticals Inc. filed an 8-K report indicating that it submitted matters to a vote of its security holders. The filing does not p
• Oramed Pharmaceuticals to Acquire N.R. Labs Ltd. — Jun 26, 2024 Risk: medium
  Oramed Pharmaceuticals Inc. announced on June 26, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of the privately held
• Oramed to Acquire InterCure for $137M — Jun 24, 2024 Risk: medium
  Oramed Pharmaceuticals Inc. announced on June 20, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of In
• Oramed Pharmaceuticals Board Changes Announced — Jun 10, 2024 Risk: medium
  Oramed Pharmaceuticals Inc. announced on June 6, 2024, a change in its board of directors. Specifically, Dr. Miriam Kidron has been appointed as a new director,
• Oramed Pharmaceuticals Announces Executive and Board Changes — May 13, 2024 Risk: medium
  Oramed Pharmaceuticals Inc. announced on May 10, 2024, a series of executive and board changes. This includes the appointment of Dr. Michal Y. Yarkoni as Chief
• Oramed Acquires Noria Therapeutics to Expand Oral Drug Pipeline — May 6, 2024 Risk: medium
  Oramed Pharmaceuticals Inc. announced on May 2, 2024, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of Nori
• Oramed Pharmaceuticals Files 8-K: Other Event — Mar 19, 2024 Risk: medium
  On March 14, 2024, Oramed Pharmaceuticals Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event itse
• Oramed Pharmaceuticals Terminates Material Agreement — Mar 18, 2024 Risk: medium
  Oramed Pharmaceuticals Inc. announced on March 18, 2024, the termination of a material definitive agreement. The company also reported on financial statements a
• Oramed Pharmaceuticals Files 8-K for 'Other Event' and Exhibits — Feb 20, 2024 Risk: medium
  Oramed Pharmaceuticals Inc. filed an 8-K on February 20, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits'. The filing indicates a curren
• ORAMED PHARMACEUTICALS ENTERS MATERIAL DEFINITIVE AGREEMENT — Jan 23, 2024
  Oramed Pharmaceuticals Inc. (ORMP) filed an 8-K on January 23, 2024, reporting a material definitive agreement entered into on January 22, 2024. This filing ind
• ORAMED PHARMACEUTICALS: Leadership/Comp Changes Reported in 8-K — Jan 19, 2024
  Oramed Pharmaceuticals Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 17, 2024, related to "Departure of Directors or Certai

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX